NEW HAVEN, CT, BioRelix Inc. has taken in $3.6 million of a planned $5.3 million equity offering, the company stated in a federal document.

According to published reports, BioRelix noted in the filing that eight investors participated in the financing, though the filing did not disclose the names of those backers. The company's board of directors includes: Campbell Murray of Novartis Venture Funds, Dov Goldstein of Aisling Capital, Philippe Chambon of New Leaf Venture Partners, Ronald Lennox of CHL Medical Partners, A. Donny Strosberg of The Scripps Research Institute, Bill Wiesler of Yale University's Office of Cooperative Research, Rob Bettigole of Elm Street Ventures, Joel Marcus of Alexandria Real Estate Equities Inc. and Brian Dixon of BioRelix.

BioRelix can advance the fight against drug resistant microbes by attacking novel targets with novel drugs. The firm has a robust in-house antimicrobial discovery platform focused on Riboswitches. RiboSwitches are the first new major class of targets for antibacterial drug discovery in decades.